Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia.
about
Treatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsHigh dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections.Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rodsInfluence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative BacilliMultidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections.Current strategies for the treatment of complicated intraabdominal infections.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.To B or not to B, that is the question: is it time to replace colistin with polymyxin B?Colistin: efficacy and safety in different populations.Strategies for the safe use of colistin.The safety of polymyxin antibiotics.Good tolerability of high dose colistin-based therapy in patients with haematological malignancies.Colistin: still a lifesaver for the 21st century?The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study.Successful use of extracorporeal membrane oxygenation in a human immunodeficiency virus infected patient with severe acute respiratory distress syndrome.Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia.Efficacy and Safety of a Colistin Loading Dose, High-Dose Maintenance Regimen in Critically Ill Patients With Multidrug-Resistant Gram-Negative Pneumonia.Outcomes in meningitis/ventriculitis treated with intravenous or intraventricular plus intravenous colistin.Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study.High-dose colistin for microbiologically documented serious respiratory infections associated with carbapenem-resistant Acinetobacter baummannii in critically ill cancer patients: a retrospective cohort study.Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.
P2860
Q28082546-A955821E-A8DF-4EB3-8ADA-6F718D4C81A0Q33754471-20D4542D-BED1-4D10-8445-8BA266FB4BAEQ34552966-87220643-ADB2-4DAB-AF25-B0B879BD280BQ34955582-D7DACDE7-8864-4F5A-95A0-63188B0A5A1AQ34974577-00DB076C-0106-4079-B1B0-469CE1FDE9CDQ36158501-D01380BE-ECC5-4197-8799-C1C63E588621Q36438905-D9702B33-D8EE-4A48-A715-19EE062CE565Q36761826-AE87EC13-CF15-4C9B-81FA-6E8132A33EC8Q38088261-CFC27BC6-4C2D-40C0-BDA7-D0C05AA7F517Q38123247-16C1E562-74BD-4632-B015-3A51FC31B641Q38138835-19E2EBB2-98FE-43F5-A9E8-D43C105F67A6Q38262205-82BDAB4D-0458-465E-8FDF-C5879884AD45Q38262873-9A4B36D4-1074-4A9E-83C9-D854FFAD4215Q38514980-CF0EFD6A-8575-4D84-A373-72A72169BBFEQ38548658-65BCCB11-F7ED-4872-83FC-68A23CC35BEAQ38586123-D3B9E697-21A1-4A64-8A7C-39DD47AD91CAQ38869608-CC11BE19-626C-4527-AEF8-7DF81748CD15Q38940249-77914597-F5C8-4ED6-B076-EE3ABF1A621FQ39236424-9DD4F67B-924C-4ED2-A3A9-7E9CD446A21FQ40223593-BC0D89C1-B64A-403C-A517-1BEA7D4BA8FCQ40283541-0C2A246A-7EA8-4C88-A7BC-C7E981CAD4A1Q40657458-C8B08EAB-0420-43AE-BC34-D34BB14D235CQ40690344-89FC67C7-B9A0-4D3E-865B-72865689E5ECQ40821276-5290193A-66A2-4FC6-BE16-4819F73F5212Q41007716-613C796C-8441-4CFD-A9F6-61BDBED6982DQ41179174-D57DF020-CA92-4FD6-8B8B-96B2304A2040Q41532045-596EC629-67C9-4CB7-A648-BBD9C822240AQ44160090-3F43B15E-9F69-4106-A3BF-E309E19C5AA5Q44181170-453575C3-D414-4F50-BEDB-F7D659D4FE81Q52695014-B5C979F7-9A9D-41AC-9B5A-EF2C6470FAFE
P2860
Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Association between colistin d ...... tant gram-negative bacteremia.
@en
Association between colistin d ...... tant gram-negative bacteremia.
@nl
type
label
Association between colistin d ...... tant gram-negative bacteremia.
@en
Association between colistin d ...... tant gram-negative bacteremia.
@nl
prefLabel
Association between colistin d ...... tant gram-negative bacteremia.
@en
Association between colistin d ...... tant gram-negative bacteremia.
@nl
P2093
P2860
P356
P1476
Association between colistin d ...... tant gram-negative bacteremia.
@en
P2093
Elizabeth A Neuner
Giulia Vicari
Seth R Bauer
Simon W Lam
P2860
P304
P356
10.1093/CID/CIS909
P407
P577
2012-10-22T00:00:00Z